The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The diagnostics company reported organic sales increased 4 percent in Q4 and 7 percent in 2015, and set a growth target of 6 percent to 8 percent for 2016.
The molecular diagnostics developer will use the money to continue expanding its commercial presence in the cancer diagnostics market.
The companies will investigate the feasibility of using BioTheranostics’ proprietary biomarkers and DeNovos CTC platform for blood-based diagnostics.
NEW YORK (GenomeWeb) – BioTheranostics today said that it has received a positive coverage and reimbursement evaluation from a Medicare contractor for its Breast Cancer Index test.
BioTheranostics Nicolas Barthelemy its new president and CEO. He succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.
Originally published Sept. 22.
NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.
Researchers describe a way to share data while keeping it secure, Agence France Presse reports.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.
A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.